Importer & Manufacturer | Source: CDSCO
Published On: 18-05-2026
Enforcement Date: 27 March, 2026
Strengthening Enforcement against Unauthorized Promotion and Distribution of GLP-1 Based Drugs
The Central Drugs Standard Control Organization (CDSCO) has directed all State and Union Territory Drug Controllers to intensify enforcement against unauthorised promotion, illegal distribution, and misuse of GLP-1 based weight loss drugs such as semaglutide and tirzepatide products. Authorities have been asked to monitor online and offline sales channels, promotional activities, and ensure compliance with approved indications, labelling, and prescription requirements.
The Central Drugs Standard Control Organization (CDSCO) issued a circular instructing State and Union Territory Drug Controllers to strengthen enforcement against unauthorised promotion and distribution of GLP-1 based weight loss drugs.
Key points include:
- The directive follows nationwide inspections and audits conducted with State Licensing Authorities targeting illegal distribution channels, non-compliant dispensing practices, and misuse of GLP-1 drugs across online pharmacies, wholesalers, retail outlets, wellness clinics, and slimming centres.
- CDSCO emphasised strict adherence to approved indications, label warnings, and authorised supply chain practices for manufacturing, import, distribution, retail, and dispensing activities.
- The circular also calls for active monitoring of digital, social media, print, and outdoor advertisements related to these drugs and directs authorities to initiate action under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and the Drugs and Cosmetics Act, 1940 against violators.
- Coordination with ASCI and other agencies for effective enforcement has also been recommended.
Applicable For: Importer & Manufacturer
Reference Number: F. No. Enforc-11021(11)/34/2026-eoffice-Part(1)
Notification Link